ZFIN ID: ZDB-FISH-180725-11
Fish name: nr1h3z101a/z101a
Genotype: nr1h3z101a/z101a
Targeting Reagent: none
HUMAN DISEASE MODELED by nr1h3z101a/z101a
No data available
GENE EXPRESSION
Gene expression in nr1h3z101a/z101a
Protein expression No data available
Reporter gene expression No data available
PHENOTYPE
Phenotype in nr1h3z101a/z101a
Phenotype Conditions Figures
blood plasma cholesterol increased amount, exacerbated high cholesterol Fig. 3 from Benítez-Santana et al., 2017
blood plasma triglyceride increased amount, abnormal chemical treatment by gavage: cholesteryl oleate, chemical treatment by gavage: triolein, chemical treatment by gavage: CholEsteryl BODIPY 542/563 C11 Fig. 2 from Benítez-Santana et al., 2017
female organism intestine acaca expression increased amount, abnormal control Fig. 5 from Benítez-Santana et al., 2017
female organism intestine srebf1 expression increased amount, abnormal control Fig. 5 from Benítez-Santana et al., 2017
female organism lipoprotein lipase activity decreased process quality, abnormal chemical treatment by injection: tyloxapol Fig. 2 from Benítez-Santana et al., 2017
female organism liver abca1a expression decreased amount, abnormal control Fig. 5 from Benítez-Santana et al., 2017
intestinal lipid absorption increased occurrence, abnormal chemical treatment by gavage: cholesteryl oleate, chemical treatment by gavage: triolein, chemical treatment by gavage: CholEsteryl BODIPY 542/563 C11 Fig. 1 from Benítez-Santana et al., 2017
liver cholesterol increased amount, abnormal high cholesterol Fig. 4 from Benítez-Santana et al., 2017
liver cholesteryl ester increased amount, abnormal high cholesterol Fig. 4 from Benítez-Santana et al., 2017
male organism intestine acaca expression decreased amount, abnormal control Fig. 5 from Benítez-Santana et al., 2017
male organism intestine srebf1 expression increased amount, abnormal control Fig. 5 from Benítez-Santana et al., 2017
male organism intestine fasn expression increased amount, abnormal control Fig. 5 from Benítez-Santana et al., 2017
male organism liver abca1b expression decreased amount, abnormal control Fig. 5 from Benítez-Santana et al., 2017
male organism liver abca1a expression decreased amount, abnormal control Fig. 5 from Benítez-Santana et al., 2017
male organism triglyceride increased amount, abnormal chemical treatment by gavage: cholesteryl oleate, chemical treatment by gavage: triolein, chemical treatment by gavage: CholEsteryl BODIPY 542/563 C11 Fig. 2 from Benítez-Santana et al., 2017
vasculature lipid increased amount, exacerbated chemical treatment by gavage: cholesteryl oleate, chemical treatment by gavage: triolein, chemical treatment by gavage: CholEsteryl BODIPY 542/563 C11 Fig. 1 from Benítez-Santana et al., 2017

CITATIONS  (1)